PuSH - Publikationsserver des Helmholtz Zentrums München

Guttman-Yassky, E.* ; Brunner, P.M.* ; Neumann, A.U. ; Khattri, S.* ; Pavel, A.B.* ; Malik, K.A.* ; Singer, G.K.* ; Baum, D.* ; Gilleaudeau, P.* ; Sullivan-Whalen, M.* ; Rose, S.* ; Jim On, S.* ; Li, X.* ; Fuentes-Duculan, J.* ; Estrada, Y.* ; Garcet, S.* ; Traidl-Hoffmann, C. ; Krueger, J.G.* ; Lebwohl, M.G.*

Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.

J. Am. Acad. Dermatol. 78, 872-881.e6 (2018)
Verlagsversion DOI
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
Purpose of Review Advances in technology have expanded telemedicine opportunities covering medical practice, research, and education. This is of particular importance in movement disorders (MDs), where the combination of disease progression, mobility limitations, and the sparse distribution of MD specialists increase the difficulty to access. In this review, we discuss the prospects, challenges, and strategies for telemedicine in MDs.Recent Findings Telemedicine for MDs has been mainly evaluated in Parkinson's disease (PD) and compared to in-office care is cost-effective with similar clinical care, despite the barriers to engagement. However, particular groups including pediatric patients, rare MDs, and the use of telemedicine in underserved areas need further research.Summary Interdisciplinary telemedicine and tele-education for MDs are feasible, provide similar care, and reduce travel costs and travel time compared to in-person visits. These benefits have been mainly demonstrated for PD but serve as a model for further validation in other movement disorders.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Atopic Dermatitis ; Fezakinumab ; Il-22 ; Placebo-controlled Trial ; Moderate-to-severe Ad; Randomized Controlled-trial; Chronic Tic Disorders; Parkinsons-disease; Health-care; Tourette-syndrome; Behavior-therapy; Neurological Disorders; Huntington Disease; Batten-disease; Virtual Visits
ISSN (print) / ISBN 0190-9622
e-ISSN 1097-6787
Quellenangaben Band: 78, Heft: 5, Seiten: 872-881.e6 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort 233 Spring St, New York, Ny 10013 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Environmental Medicine (IEM)